Kashiwabara Kosuke, Semba Hiroshi, Fujii Shinji, Tsumura Shinsuke, Aoki Ryota
Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan
Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan.
Anticancer Res. 2015 Feb;35(2):1065-71.
It is not clear whether there is a difference in benefit of chemotherapy between small cell lung cancer (SCLC) patients with pre-existing idiopathic interstitial pneumonias (IIPs) and non-small cell lung cancer (NSCLC) patients with IIPs.
We performed a retrospective study of the overall survival (OS) between advanced lung cancer patients with IIPs (n=28) and those without IIPs (n=145).
The OS in NSCLC patients with IIPs was shorter than in those without IIPs (median OS, 10.6 vs. 27.9 months, p=0.008) but the OS in SCLC patients with IIPs was not inferior to that of those without IIPs (12.7 vs. 14.8 months, p=0.835). Multivariate analysis showed that the small number of regimens increased the risk of mortality, instead of pre-existing IIPs.
The continuation of chemotherapy in SCLC patients with IIPs made it possible to have a similar prognosis to that in those without IIPs.
既往患有特发性间质性肺炎（IIP）的小细胞肺癌（SCLC）患者与患有IIP的非小细胞肺癌（NSCLC）患者在化疗获益方面是否存在差异尚不清楚。
我们对患有IIP的晚期肺癌患者（n = 28）和未患有IIP的晚期肺癌患者（n = 145）的总生存期（OS）进行了一项回顾性研究。
患有IIP的NSCLC患者的OS短于未患有IIP的患者（中位OS，10.6个月对27.9个月，p = 0.008），但患有IIP的SCLC患者的OS并不低于未患有IIP的患者（12.7个月对14.8个月，p = 0.835）。多因素分析表明，化疗方案数量少会增加死亡风险，而非既往存在的IIP。
患有IIP的SCLC患者继续化疗使其有可能获得与未患有IIP的患者相似的预后。
